Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГБУ ВО «Ростовский государственный медицинский университет», Ростов-на-Дону, Россия; 2 ФГБУ ВО «Волгоградский государственный медицинский университет», Волгоград, Россия; 3 ГБУЗ «Областная клиническая психиатрическая больница № 2», Волгоград, Россия
Список исп. литературыСкрыть список 1. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010; 186: 113–37. 2. Азаматова В.В., Анцыборов А.В., Бойко Е.О. и др. Краткий курс психиатрии. Учебник для последипломного образования. Ростов-на-Дону, 2019. / Azamatova V.V., Antsyborov A.V., Boiko E.O. i dr. Kratkii kurs psikhiatrii. Uchebnik dlia poslediplomnogo obrazovaniia. Rostov-na-Donu, 2019. [in Russian] 3. Крючкова М.Н., Солдаткин В.А. Синдром хронической тазовой боли: психопатологические аспекты. Вестн. урологии. 2017; 5 (1): 52–63. / Kriuchkova M.N., Soldatkin V.A. Sindrom khronicheskoi tazovoi boli: psikhopatologicheskie aspekty. Vestn. urologii. 2017; 5 (1): 52–63. [in Russian] 4. Тювина Н.А. Депрессия у женщин. М.: Кафедра психиатрии и медицинской психоневрологии ММА им. И.М.Сеченова, 2003; с. 32–62. / Tiuvina N.A. Depressiia u zhenshchin. M.: Kafedra psikhiatrii i meditsinskoi psikhonevrologii MMA im. I.M.Sechenova, 2003; s. 32–62. [in Russian] 5. Краснов В.Н. Расстройства аффективного спектра. М.: Практическая медицина, 2010; с. 47–8. / Krasnov V.N. Rasstroistva affektivnogo spektra. M.: Prakticheskaia meditsina, 2010; s. 47–8. [in Russian] 6. Nolen-Hoeksema S. Gender differences in coping with depression across the lifespan. Depression 1998; 3: 81–90. 7. Агибалова Т.В., Александровский Ю.А., Бочеева Е.А. и др. Посттравматическое стрессовое расстройство. Международная (Россия – Армения – Беларусь – Украина) коллективная монография. Ростов-на-Дону, 2015. / Agibalova T.V., Aleksandrovskii Iu.A., Bocheeva E.A. i dr. Posttravmaticheskoe stressovoe rasstroistvo. Mezhdunarodnaia (Rossiia – Armeniia – Belarus' – Ukraina) kollektivnaia monografiia. Rostov-na-Donu, 2015. [in Russian] 8. Martin LA, Neighbors HW, Griffith DM. The experience of symptoms of depression in men vs women: analysis of the National Comorbidity Survey Replication. JAMA Psychiatry 2013; 70: 1100–6. 9. Zierau F, Bille A, Rutz W, Bech P. The Gotland Male Depression Scale: a validity study in patients with alcohol use disorders. Nordic J Psychiatry 2002; 56: 265–71. 10. Тювина Н.А. Депрессии у женщин. М.: Сервье, 2006. / Tiuvina N.A. Depressii u zhenshchin. M.: Serv'e, 2006. [in Russian] 11. Тювина Н.А., Балабанова В.В., Воронина Е.О. Депрессии у женщин, манифестирующие в период климактерия. Журн. неврологии и психиатрии. 2017; 3: 22–7. / Tiuvina N.A., Balabanova V.V., Voronina E.O. Depressii u zhenshchin, manifestiruiushchie v period klimakteriia. Zhurn. nevrologii i psikhiatrii. 2017; 3: 22–7. [in Russian] 12. Коган М.И., Ибишев Х.С., Васильев О.Н. Возрастной андрогенный дефицит. Этиология, диагностика, лечение: учебно-методическое пособие. Ростов на Дону, 2010. / Kogan M.I., Ibishev Kh.S., Vasil'ev O.N. Vozrastnoi androgennyi defitsit. Etiologiia, diagnostika, lechenie: uchebno-metodicheskoe posobie. Rostov na Donu, 2010. [in Russian] 13. Nieschlag E, Behre HM. Testosterone: Action. Deficiency. Substitution. 4th ed. Cambridge: Cambridge University Press, 2012. 14. Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res 1997; 52: 1–32. 14. Banerjee PP, Banerjee S, Brown TR, Zirkin BR. Androgen action in prostate function and disease. Am J Clin Exp Urol 2018; 6 (2): 62–77. 16. Андрология. Мужское здоровье и дисфункция репродуктивной системы. Под общ. ред. Э. Нишлага, Г.М. Бере. М., 2005. / Andrologiia. Muzhskoe zdorov'e i disfunktsiia reproduktivnoi sistemy. Pod obshch. red. E. Nishlaga, G.M. Bere. M., 2005. [in Russian] 17. Kaufman JM. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26 (6): 833–76. DOI: 10.1210/er.2004-0013 18. Mulligan T et al. Prevalence of hypogonadism in males aged at least 45years: the HIM study. Int J Clin Pract 2006; 6: 762–9. 19. Huhtaniemi I. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis, and treatment. Asian J Androl 2014; 16: 192–202. 20. Коган М.И. и др. Тестостерон: от сексуальности к метаболическому контролю: монография. Ростов на Дону: Феникс, 2017. / Kogan M.I. i dr. Testosteron: ot seksual'nosti k metabolicheskomu kontroliu: monografiia. Rostov na Donu: Feniks, 2017. [in Russian] 21. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. Drug Healthc Patient Saf 2010; 2: 141–50. 22. Safarineiad MR. Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. J Clin Psychopharmacol 2008; 28: 418–23. 23. Van Honk J, Tuiten A, Verbaten R et al. Correlations among salivary testosterone, mood, and selective attention to threat in humans. Horm Behav 1999; 36 (1): 17–24. 24. Van Honk J, Schutter DJ. Testosterone reduces conscious detection of signals serving social correction: Implications for antisocial behavior. Psychol Sci 2007; 18 (8): 663–7. 25. Amanatkar HR, Chibnall JT, Seo BW, et al. Impact of exogenous testosterone on mood: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Clin Psychiatry 2014; 26 (1): 19–32. 26. Wooderson SC, Gallagher P, Watson S, Young AH. An exploration of testosterone levels in patients with bipolar disorder. BJPsych Open 2015; 1 (2): 136–8. Doi: 10.1192/bjpo.bp.115.001008 27. Rodgers S, Holtforth M, Hengartner M et al. Serum Testosterone Levels and Symptom-Based Depression Subtypes in Men. Front Psychiatry 2015; 6: 61. DOI: 10.3389/fpsyt.2015.00061 28. Ford AH, Yeap BB, Flicker L et al. Prospective longitudinal study of testosterone and incident depression in older men: The Health In Men Study. Psychoneuroendocrinology 2016; 64: 57–65. DOI: 10.1016/j. psyneuen.2015.11.012 29. Westley CJ, Amdur RL, Irwig MS. High Rates of Depression and Depressive Symptoms among Men Referred for Borderline Testosterone Levels. J Sex Med 2015; 12 (8): 1753–60. DOI: 10.1111/jsm.12937 30. Hsu B, Cumming RG, Blyth FM et al. The longitudinal relationship of sexual function and androgen status in older men: the Concord Health and Ageing in Men Project. J Clin Endocrinol Metab 2015; 100 (4): 1350–8. DOI: 10.1210/jc.2014-4104 31. Oyola MG, Handa RJ. Hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes: sex differences in regulation of stress responsivity. Stress (Amsterdam, Netherlands) 2017; 20 (5): 476–94. DOI: 10.1080/10253890.2017.1369523 32. Kranz GS, Wadsak W, Kaufmann U et al. High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People. Biol Psychiatry 2015; 78 (8): 525–33. DOI: 10.1016/j.biopsych.2014.09.010 33. Giltay EJ, Enter D, Zitman FG et al. Salivary testosterone: associations with depression, anxiety disorders, and antidepressant use in a large cohort study. J Psychosom Res 2012; 72 (3): 205–13. DOI: 10.1016/j.jpsychores.2011.11.014 34. McHenry J, Carrier N, Hull E, Kabbaj M. Sex Differences in Anxiety and Depression: Role of Testosterone. Front Neuroendocrinol 2014; 35 (1): 42–57. DOI: 10.1016/j.yfrne.2013.09.001 35. Heany SJ, van Honk J, Stein DJ et al. A quantitative and qualitative review of the effects of testosterone on the function and structure of the human social-emotional brain. Metab Brain Dis 2016; 31: 157–67. 36. Shores MM, Sloan KL, Matsumoto AM et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry 2004; 61: 162–7. 37. Zarrouf FA, Artz S, Griffith, J et al. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009; 15: 289–305. 38. Di Blasio CJ, Hammett J, Malcolm JB et al. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. Can J Urol 2008; 15: 4249–56. 39. Chung SD, Kao LT, Lin HC et al. Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder. PLoS One 2017; 12: e0173266. 40. Dinh KT, Reznor G, Muralidhar V et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol 2016; 34: 1905–12. 41. Wu F, Tajar A, Beynon JM et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123–35. 42. Grossmann M, Matsumoto A. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. J Clin Endocrinol Metab 2017; 102: 1067–75. 43. Frye CA, Lacey EH. Posttraining androgens’ enhancement of cognitive performance is temporally distinct from androgens’ increases in affective behavior. Cogn Affect Behav Neurosci 2001; 1: 172–82. 44. Gutierrez-Garcia AG, Contreras CM, Vasquez-Hernandez DI et al. Testosterone reduces cumulative burying in female Wistar rats with minimal participation of estradiol. Pharmacol Biochemistry Behavior 2009; 93: 406–12. 45. Estrada-Camarena E, Fernandez-Guasti A, Lopez-Rubalcava C. Antidepressant-like effect of different estrogenic compounds in the forced swimming test. Neuropsychopharmacology 2003; 28: 830–8. 46. Carrier N, Kabbaj M. Testosterone and imipramine have antidepressant effects in socially isolated male but not female rats. Horm Behav 2012; 61 (5): 678–85. DOI: 10.1016/j.yhbeh.2012.03.001 47. Miller KK, Perlis RH, Papakostas GI et al. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr 2009; 14: 688–94. 48. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682–8. 49. Hermans EJ, Putman P, Baas JM et al. Exogenous testosterone attenuates the integrated central stress response in healthy young women. Psychoneuroendocrinology 2007; 32: 1052–61. 50. Goldstat R, Briganti E, Tran J et al. Transdermal testosterone therapy improves wellbeing, mood, and sexual function in premenopausal women. Menopause 2003; 10: 390–8. 51. Schmidt PJ, Nieman L, Danaceau MA et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstetrics and Gynecology 2000; 183 (2): 414–20. 52. Gleason CE, Dowling ME, Wharton W et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Medicine 2015; 12 (6): e1001833. 53. Whedon JM, KizhakkeVeettil A, Rugo NA, Kieffer KA. Bioidentical estrogen for menopausal depressive symptoms: a systematic review and meta-analysis. J Womens Health 2017; 26 (1): 18–28. 54. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of The North American Menopause Society. Menopause 2005; 12 (5): 496–511. 55. Pope HG, Amiaz R, Brennan BP et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacology 2010; 30 (2): 126–34. 56. Chávez-Castillo M, Núñez V, Nava M et al. Depression as a Neuroendocrine Disorder: Emerging Neuropsychopharmacological Approaches beyond Monoamines. Advances Pharmacological Sci 2019; 2019: 7943481. DOI: 10.1155/2019/7943481 57. Rohr UD. The impact of testosterone imbalance on depression and women’s health. Maturitas 2002; 41 (Suppl. 1): S25–46. 58. Hendrick V, Gitlin M, Altshuler L, Korenman S. Antidepressant medications, mood and male fertility. Psychoneuroendocrinology 2000; 25 (1): 37–51. 59. Rosenber KP, Bleiberg KL, Koscis J, Gross C. A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance. J Sex Marital Ther 2003; 29 4: 289–96. 60. Kennedy SH, Eisfeld BS, Dickens SE et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000; 61 (4): 276–81. 61. Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRISexual Dysfunction: Preclinical to Clinical. Is It Fact or Fiction? Sex Med Rev 2018; 6: 217–23. 62. Almeida OP, Yeap BB, Hankey GJ et al. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry 2008; 65: 283–9. 63. Hintikka L, Niskanen H, KoivumaaHonkanen T et al. Viinamaki Hypogonadism, decreased sexual desire, and long-term depression in middle-aged men. J Sex Med 2009; 6: 2049–57. 64. Jacobsen NW, Hansen CH, Nellemann C et al. Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro 2015; 29 (7): 1729–35. DOI: 10.1016/j.tiv.2015.07.005 65. Hansen CH, Larsen LW, Sørensen AM et al. The six most widely used selective serotonin reuptake inhibitors decrease androgens and increase estrogens in the H295R cell line. Toxicol In Vitro 2017; 41: 1–11. DOI: 10.1016/j.tiv.2017.02.001 66. Bataineh HN, Daradka T. Effects of long‐term use of fluoxetine on fertility parameters in adult male rats. Neuro Endocrinol Lett 2007; 28, 321–5. 67. Muller JC, Imazki PH, Boareto AC et al. In vivo and in vitro estrogenic activity of the antidepressant fluoxetine. Reprod Toxicol 2012; 34: 80–5. 68. Tanrikut C, Feldman AS, Altemus M et al. Adverse effect of paroxetine on sperm. Fertil Steril 2010; 94: 1021–6. 69. Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion. J Clin Psychiatry 2001; 3 (1): 22–7. 70. Nørr L, Bennedsen B, Fedder Jens, Larsen Erik. Use of selective serotonin reuptake inhibitors reduces fertility in men. Andrology 2016; 4 (3): 389–94. DOI: 10.1111/andr.12184 71. Wang C, Alexander G, Berman N et al. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996; 81, 3578–83. 72. Seidman SN, Rabkin JG.Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998; 48 (2–3): 157–61. 73. Elliott J, Kelly SE, Millar AC et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open 2017; 7 (11): e015284. 74. Amiaz R, Seidman SN. Testosterone and depression in men. Curr Opin Endocrinol Diabetes Obes 2008; 15 (3): 278–83. DOI: 10.1097/MED. 0b013e3282fc27eb 75. Giltay EJ, van der Mast RC, Lauwen E et al. Plasma Testosterone and the Course of Major Depressive Disorder in Older Men and Women. Am J Geriatr Psychiatry 2017; 25 (4): 425–437. DOI: 10.1016/j.jagp. 2016.12.014